Cardiovascular diseases (CVDs) are said to be the major reason for deaths worldwide. According to the statistics, approximately four out of five fatalities are owing to stroke or myocardial infarction. Efforts to avoid CVD have a slight effect on the reduction of the number of CVD-associated deaths despite numerous medical progress. Thus, the hunt for novel and even better treatments and therapies for the betterment of those who are living with CVD is still in progress.
The metabolomics field has presented a great option for treating these diseases. Metabolomic biomarkers assist doctors to identify the threat of CVD and take preventive actions before the diseases can emerge. Prompt diagnosis of CVD is a good indication for an individual’s recovery and their health as well. So, the need for trustworthy, responsive, and non-invasive biomarkers that can work as therapeutic targets to avoid and treat CVD arises. The study was carried out for the prediction of myocardial ischemia, cardiovascular disease risk, incident coronary heart disease, transient ischemic attack, and myocardial infarction risk.
On a similar note, researchers from the Johns Hopkins Medicine University revealed the results of their recent research. They analyzed data from a worldwide survey covering almost 11 Million women suffering from heart and blood vessel diseases. The study demonstrates that women frequently convey major discrepancies in the care they are offered as compared to men. And the basic reason, many women state, is that the health care providers do not respect them or listen to their problems.
American Heart Association (AHA) announced that, for decades, cardiovascular diseases such as strokes and heart attacks have been the top reason for the U.S. women fatalities. AHA also reported that minimum of 44 Million U.S. females are living with cardiovascular disease. Almost 1 in 3 women fatalities per year are due to cardiovascular disease, which is the biggest reason for the death in men as well. The results of novel research are open for access in the Journal of the American Heart Association.